Metabolic utilization of exogenous pyruvate by mutant p53 (R175H) human melanoma cells promotes survival under glucose depletion

Cancer Biology and Therapy

Volumn 12, Issue 7, 2011, Pages 647-656

  Chavez Perez, Valery A ^a   Strasberg Rieber, Mary ^a   Rieber, Manuel ^a  

^a Instituto Venezolano de Investigaciones Cientificas Centro de Microbiologia y Biologia Celular   (Venezuela)

Author keywords

Anti oxidants; Metabolic stress; p53 mutation; Superoxide dismutase

Indexed keywords

ACETYLCYSTEINE; DIPHENYLIODONIUM SALT; GLUCOSE; LACTIC ACID; PROTEIN P53; PYRUVIC ACID;

APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MELANOMA CELL; METABOLIC STRESS;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CULTURE MEDIA; ENZYME INHIBITORS; GLUCOSE; HUMANS; LACTATES; MELANOMA; MUTATION; NADPH OXIDASE; ONIUM COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; PYRUVATES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80053404569     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.7.16566     Document Type: Article

References (21)

1. Warburg O. On the origin of cancer cells. Science 1956; 123:309-14; PMID:13298683; DOI:10.1126/science.123.3191.309.
2. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66:8927-30; PMID:16982728; DOI:10.1158/0008-5472.CAN- 06-1501.
3. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2:683-93; PMID:12209157; DOI:10.1038/nrc882.
4. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 downregulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004; 64:2627-33; PMID:15059920; DOI:10.1158/0008-5472.CAN-03-0846.
5. vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH, Thompson CB. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol 2001; 21:5899-912; PMID:11486029; DOI:10.1128/MCB.21.17.5899- 912.2001.
6. Gottlieb E, Armour SM, Thompson CB. Mitochondrial respiratory control is lost during growth factor deprivation. Proc Natl Acad Sci USA 2002; 99:12801-6; PMID:12228733; DOI:10.1073/pnas.202477599.
7. Zhao Y, Coloff JL, Ferguson EC, Jacobs SR, Cui K, Rathmell JC. Glucose Metabolism Attenuates p53 and Puma-dependent Cell Death upon Growth Factor Deprivation. J Biol Chem 2008; 283:36344-53; PMID:18990690; DOI:10.1074/jbc. M803580200.
8. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009; 325:1555-9; PMID:19661383; DOI:10.1126/science. 1174229.
9. Zuckerman V, Wolyneic K, Sionov RV, Haupt S, Haupt Y. Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathol 2009; 219:3-15; PMID:19562738.
10. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. Science 2006; 312:1650-3; PMID:16728594; DOI:10.1126/science.1126863.
11. Rieber M, Strasberg-Rieber MS. DN-R175H p53 mutation is more effective than p53 interference in inducing epithelial disorganization and activation of proliferation signals in human carcinoma cells: role of E-cadherin. Int J Cancer 2009; 125:1604-12; PMID:19507255; DOI:10.1002/ijc.24512.
12. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, et al. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 1998; 16:3269-77; PMID:9681825; DOI:10.1038/sj.onc.1201867.
13. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000; 60:6788-93; PMID:11156366.
14. Park HR, Tomida A, Sato S, Tsukumo Y, Yun J, Yamori T, et al. Effect of tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst 2004; 96:1300-10; PMID:15339968; DOI:10.1093/ jnci/djh243.
15. Yun J, Tomida A, Nagata K, Tsuruo T. Glucoseregulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncol Res 1995; 7:583-90; PMID:8704275.
16. Terzian T, Torchia EC, Dai D, Robinson SE, Murao K, Stiegmann RA, et al. p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res 2010; 23:781-94; PMID:20849464; DOI:10.1111/j.1755-148X.2010.00773.x.
17. Lassam NJ, From L, Kahn HJ. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993; 53:2235-8; PMID:8485708.
18. Li G, Bush JA, Ho V. p53-dependent apoptosis in melanoma cells after treatment with camptothecin. J Invest Dermatol 2000; 114:514-9; PMID:10692111; DOI:10.1046/j.1523-747.2000.00867.x.
19. L bispecific antisense oligonucleotide. Clin Cancer Res 2001; 7:1446-51; PMID:11350916.
20. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006; 5:1136-44; PMID:16731745; DOI:10.1158/1535-7163.MCT-06-0084.
21. Kao KK, Fink MP. The biochemical basis for the anti-inflammatory and cytoprotective actions of ethyl pyruvate and related compounds. Biochem Pharmacol 2010; 80:151-9; PMID:20230800; DOI:10.1016/j. bcp.2010.03.007.